May 27, 2020 – Kainomyx is incubating in space at Cytokinetics. James Spudich, co-founder and CEO of Kainomyx, co-founded Cytokinetics, the first company devoted to developing small molecule therapeutics targeting the molecular motor-based machinery of cells, in 1998.
May 27, 2020 – Kainomyx secured $7.5M of funding to launch its programs.
April 15, 2020 – Three members have been added to the Board of Directors of Kainomyx. William J. Rutter, PhD, co-Founder of the early biotech company Chiron and multiple additional companies, is Chairman of the Board of Kainomyx. Rutter is Founder, Chairman and CEO of Synergenics, LLC, which controls a consortium of companies with different but complementary approaches to diagnosis, prevention and treatment on a worldwide basis. He joins James Spudich, PhD, CEO of Kainomyx and co-founder of Cytokinetics and MyoKardia. Dirk Thye, MD, serial entrepreneur who has led multiple small and medium sized companies in successful product development, and currently Executive Chairman at Geom Therapeutics, is an independent third member of the Board. The fourth Board member is Amit L. Mehta, PhD, a Life Science Research Foundation Fellow at Bell Labs and Stanford University in his early career, became an Associate Partner at McKinsey and Company, followed by Managing Director positions at Morgan Stanley and Goldman Sachs, and is currently Managing Director at J.P. Morgan.
February 1, 2020 – Kainomyx hired James A. Spudich to assume the position of CEO in the company.
September 4, 2019 – Kainomyx was founded by five Stanford scientists who are experts in the biology, biochemistry and biophysics of the cytoskeleton of cells – James Spudich, PhD, Annamma Spudich, PhD, Darshan Trivedi, PhD, Suman Nag, PhD, and Kathleen Ruppel, MD,PhD.